270 related articles for article (PubMed ID: 16892342)
1. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.
Specker E; Böttcher J; Brass S; Heine A; Lilie H; Schoop A; Müller G; Griebenow N; Klebe G
ChemMedChem; 2006 Jan; 1(1):106-17. PubMed ID: 16892342
[TBL] [Abstract][Full Text] [Related]
2. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
[TBL] [Abstract][Full Text] [Related]
4. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
[TBL] [Abstract][Full Text] [Related]
5. Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors.
Blum A; Böttcher J; Dörr S; Heine A; Klebe G; Diederich WE
J Mol Biol; 2011 Jul; 410(4):745-55. PubMed ID: 21762812
[TBL] [Abstract][Full Text] [Related]
6. Inhibition and catalytic mechanism of HIV-1 aspartic protease.
Silva AM; Cachau RE; Sham HL; Erickson JW
J Mol Biol; 1996 Jan; 255(2):321-46. PubMed ID: 8551523
[TBL] [Abstract][Full Text] [Related]
7. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
Martin SF; Dorsey GO; Gane T; Hillier MC; Kessler H; Baur M; Mathä B; Erickson JW; Bhat TN; Munshi S; Gulnik SV; Topol IA
J Med Chem; 1998 May; 41(10):1581-97. PubMed ID: 9572884
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization.
Specker E; Böttcher J; Heine A; Sotriffer CA; Lilie H; Schoop A; Müller G; Griebenow N; Klebe G
J Med Chem; 2005 Oct; 48(21):6607-19. PubMed ID: 16220977
[TBL] [Abstract][Full Text] [Related]
9. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
[TBL] [Abstract][Full Text] [Related]
11. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
Böttcher J; Blum A; Heine A; Diederich WE; Klebe G
J Mol Biol; 2008 Nov; 383(2):347-57. PubMed ID: 18692068
[TBL] [Abstract][Full Text] [Related]
12. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
[TBL] [Abstract][Full Text] [Related]
13. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
14. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulations of ligand-induced flap closing in HIV-1 protease approach X-ray resolution: establishing the role of bound water in the flap closing mechanism.
Singh G; Senapati S
Biochemistry; 2008 Oct; 47(40):10657-64. PubMed ID: 18785756
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of a glutamate/aspartate binding protein complexed with a glutamate molecule: structural basis of ligand specificity at atomic resolution.
Hu Y; Fan CP; Fu G; Zhu D; Jin Q; Wang DC
J Mol Biol; 2008 Sep; 382(1):99-111. PubMed ID: 18640128
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
Raza A; Sham YY; Vince R
Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317
[TBL] [Abstract][Full Text] [Related]
19. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
Smith AB; Cantin LD; Pasternak A; Guise-Zawacki L; Yao W; Charnley AK; Barbosa J; Sprengeler PA; Hirschmann R; Munshi S; Olsen DB; Schleif WA; Kuo LC
J Med Chem; 2003 May; 46(10):1831-44. PubMed ID: 12723947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]